Journal Mobile Options
Table of Contents
Vol. 21, No. 4, 2006
Issue release date: March 2006
Cerebrovasc Dis 2006;21:242–246

Efficacy of Dual Antiplatelet Therapy in Cerebrovascular Disease as Demonstrated by a Decline in Microembolic Signals

A Report of Eight Cases

Esagunde R.U. · Wong K.S. · Lee M.P. · Gan H.Y. · Wong M.C. · Chang H.M. · Chen C.L.H.
To view the fulltext, log in and/or choose pay-per-view option

Individual Users: Register with Karger Login Information

Please create your User ID & Password

Contact Information

I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in


Background: The presence of microembolic signals (MES) may indicate an increased risk of recurrent ischemic events in patients with stroke. The optimal management of such patients is uncertain. We report the effect of clopidogrel in addition to aspirin on the number of MES in a series of patients with ischemic stroke and transient ischemic attack (TIA) due to large-vessel disease. Methods: 8 patients with either extracranial or intracranial artery stenosis were identified in 30-min MES studies by transcranial Doppler sonography as having MES. All patients were on antiplatelet therapy prior to baseline transcranial Doppler monitoring. The patients were subsequently treated with clopidogrel in addition to aspirin. Repeat MES studies were performed between day 3 and 7 with aspirin and clopidogrel. Results: All patients were Chinese. The median interval time from symptom onset to initial MES study was 7 days (range of 2–30). MES donor sites included 4 severely stenosed or occluded internal carotid arteries and 4 stenosed middle cerebral arteries. The median MES number at baseline was 8 (range 3–51). Repeat MES studies showed a significant decrease in MES (p = 0.012, Wilcoxon signed ranks test). 4 patients had complete cessation of MES and all patients showed a decline in MES. No patient had recurrent strokes or bleeding complications. Conclusion: The rapid and significant decline of MES in our stroke and TIA patients suggests the possible efficacy of dual antiplatelet therapy with aspirin and clopidogrel in patients with MES and symptomatic large-artery occlusive disease. Randomized controlled trials should be conducted to confirm this preliminary observation.

Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.


  1. Koennecke HC, Mast H, Trocio SH, Sacco RL, Ma W, Mohr JP, Thompson JLP: Frequency and determinants of microembolic signals on trancranial Doppler in unselected patients with acute carotid territory ischemia: a prospective study. Cerebrovasc Dis 1998;8:107–112.
  2. Babikian VL, Wijman C, Hyde C, Cantelmo NL, Winter MR, Baker E, Pochay V: Cerebral microembolism and early recurrent cerebral or retinal ischemic events. Stroke 1997;28:1314–1318.
  3. Siebler M, Nachtmann A, Sitzer M, Rose G, Kleinschmidt A, Rademacher J, Steinmetz H: Cerebral microembolism and the risk of ischemia in asymptomatic high grade internal carotid artery stenosis. Stroke 1995;26:2184–2186.
  4. Tegeler CH, Burke GL, Dalley GM, Stump DA: Carotid emboli predict poor outcome in stroke. Stroke 1993;24:186.
  5. Valton L, Larue V, le Traon AP, Massabuau P, Geraud G: Microembolic signals and risk of early recurrence in patients with stroke or transient ischemic attack. Stroke 1998;29:2125–2128.
  6. Ries S, Schminke U, Daffertshofer M, Schindlmayr C, Hennerici M: High intensity transient signals and carotid artery disease. Cerebrovasc Dis 1995;5:124–127.

    External Resources

  7. Forteza AM, Babikian VL, Hyde C, Winter M, Pochay V: Effect of time and cerebrovascular symptoms on the prevalence of microembolic signals in patients with cervical carotid stenosis. Stroke 1996;27:687–690.
  8. Sliwka U, Job FP, Wissuwa D, Diehl RR, Flachskampf FA, Hanrath P, Noth J: Occurrence of transcranial Doppler high-intensity transient signals in patient with potential cardiac sources of embolism. Stroke 1995;26:2067–2070.
  9. Sliwka U, Lingnau A, Stohlmann WD, Schmidt P, Mull M, Diehl RR, Noth J: Prevalence and time course of microembolic signals in patients with acute stroke: a prospective study. Stroke 1997;28:358–363.
  10. Sturzenegger M, Beer JH, Rihs F: Monitoring combined anti-thrombotic treatments in patients with prosthetic heart valves using transcranial Doppler and coagulation markers. Stroke 1995;26:63–69.
  11. Droste DW, Junker K, Hansberg T, Dittrich R, Ritter M, Ringelstein EB: Circulating microemboli in 33 patients with intracranial arterial stenosis. Cerebrovasc Dis 2002;13:26–30.
  12. Goertler M, Baeumer M, Kross R, Blaser T, Lutze G, Jost S, Wallesch CW: Rapid decline of cerebral microemboli of arterial origin after intravenous acetylsalicylic acid. Stroke 1999;30:66–69.
  13. Goertler M, Blaser T, Krueger S, Hofmann K, Baeumer M, Wallesch CW: Cessation of embolic signals after antithrombotic prevention is related to reduced risk of recurrent arterioembolic transient ischaemic attack and stroke. J Neurol Neurosurg Psychiatry 2002;72:338–342.
  14. Droste DW, Sonne M, Siemens HJ, Kaps M: Asymptomatic circulating cerebral emboli and cerebral blood flow velocity under aspirin and ticlopidine in patients with cerebrovascular disease. Neurol Res 1996;18:449–453.
  15. Takada T, Akiyama H, Moriyasu H, Minematsu K, Yamaguchi T: Disappearance of embolic signals on transcranial Doppler sonography following antiplatelet therapy in a patient with transient ischemic attacks. Rinsho Shinkeigaku 1998;38:329–332.
  16. European Carotid Surgery Trialist Group: Risk of stroke in the distribution of an asymptomatic carotid artery. Lancet 1995;345:209–212.
  17. Baumgartner RW, Mattle HP, Schroth G: Assessment of >50% and <50% intracranial stenoses by transcranial color-coded sonography. Stroke 1999;30:87–92.
  18. Ringelstein EB, Droste DW, Babikian VL, Evans DH, Grosset DG, Kaps M, Markus HS, Russell D, Siebler M: Consensus on microembolus detection by TCD. Stroke 1998;29:725–729.
  19. NASCET Collaborators: Beneficial effect of carotid endarterectomy in symptomatic patients with high-grade stenosis. N Engl J Med 1991;325:445–453.
  20. Sliwka U, Klotzch C, Popescu O, Brandt K: Do chronic middle cerebral artery stenoses represent an embolic focus? Stroke 1997;28:1324–1327.
  21. Lund C, Rygh J, Stensrod B, Sandset PM, Brucher R, Russell D: Cerebral microembolus detection in an unselected acute ischemic stroke population. Cerebrovasc Dis 2000;10:403–408.
  22. Kaposta Z, Baskerville PA, Madge D, Fraser S, Martin JF, Markus HS: L-Arginine and S-nitrosoglutathione reduce embolization in humans. Circulation 2001;103:2321–2322.

    External Resources

  23. Herbert JM, Dol F, Bernat A, Falotico R, Lale A, Savi P: The antiaggregating and antithrombotic activity of clopidogrel is potentiated by aspirin in several experimental models in the rabbit. Thromb Haemost 1998;80:512–518.
  24. Moshfegh K, Redondo M, Julmy F, Wuillemin WA, Gebauer MU, Haeberli A, Meyer BJ: Antiplatelet effects of clopidogrel compared with aspirin after myocardial infarction: enhanced inhibitory effects of combination therapy. J Am Coll Cardiol 2000;36:699–705.
  25. The Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators: Effects of clopidogrel in addition to aspirin in patients with acute coronary syndrome without ST-segment elevation. N Engl J Med 2001;345:494–502.
  26. Diener HC, Bogousslavsky J, Brass LM, Cimminiello C, Csiba L, Kaste M, Leys D, Matias-Guiu J, Rupprecht HJ: Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischemic attack in high-risk patients (MATCH): randomized, double-blind, placebo-controlled trial. Lancet 2004;364:331–337.
  27. Markus H: The effect of dual antiplatelet therapy compared with aspirin on asymptomatic embolization in carotid stenosis: the CARESS trial. Proc 13th Eur Stroke Congr, Mannheim-Heidelberg, May 2004.

Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50